GlassScriptPhysician profile
Heather Dains
NPI 1760967533
$3,523.83
in general payments reported to CMS, 2019-2025
37 companies · $1,508 in 2025
The $1,508 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.27 · 2022: $703 · 2023: $639 · 2024: $577 · 2025: $1,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,526 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,526.26 |
| Education | $197.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $516.75 | 2021-2025 | Datroway, Enhertu |
| Merck Sharp & Dohme LLC | $377.54 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $232.75 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Seagen INC. | $213.61 | 2022-2023 | Tukysa |
| Aveo Pharmaceuticals, INC. | $204.72 | 2024-2025 | |
| Janssen Biotech, INC. | $195.85 | 2022-2025 | Tecvayli, Erleada, Carvykti |
| Eisai INC. | $166.54 | 2022-2025 | |
| Genzyme Corporation | $121.02 | 2022-2025 | |
| Taiho Oncology, INC. | $112.18 | 2024-2025 | |
| Abbvie INC. | $107.28 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $104.94 | 2025 | Myrisk |
| Stemline Therapeutics INC. | $86.58 | 2024-2025 | Orserdu |
| Sanofi-Aventis U.S. LLC | $77.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.63 | 2022-2023 | Cuvitru |
| Novartis Pharmaceuticals Corporation | $73.84 | 2022-2025 | Kisqali, Piqray |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $73.18 | 2024-2025 | Libtayo |
| Astellas Pharma US INC | $68.30 | 2024-2025 | Vyloy |
| Pfizer INC. | $67.99 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $66.38 | 2021-2025 | Onivyde |
| Tersera Therapeutics LLC | $48.69 | 2025 | Quzyttir |
| Bayer Healthcare Pharmaceuticals INC. | $48.45 | 2022 | |
| Amgen INC. | $47.86 | 2021-2024 | Tavneos |
| Daiichi Sankyo INC. | $46.53 | 2022-2025 | Enhertu |
| Celgene Corporation | $46.25 | 2022-2025 | Reblozyl |
| Janssen Scientific Affairs, LLC | $44.31 | 2023 | Darzalex, Tecvayli |
| Incyte Corporation | $42.05 | 2022-2025 | Monjuvi |
| Sobi, INC | $39.25 | 2022 | |
| Caris Mpi, INC. | $34.49 | 2025 | Mi Cancer Seek |
| Pharmacyclics LLC, An Abbvie Company | $26.29 | 2023 | Epkinly |
| G1 Therapeutics, INC. | $25.05 | 2023 | Cosela |
| Dendreon Pharmaceuticals LLC | $23.45 | 2025 | Provenge |
| Foundation Medicine, INC. | $21.91 | 2023 | |
| Puma Biotechnology, INC. | $20.06 | 2023 | Nerlynx |
| Coherus Oncology, INC. | $19.31 | 2025 | Loqtorzi |
| Kyowa Kirin, INC. | $19.05 | 2021 | |
| Gilead Sciences, INC. | $14.61 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $12.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Dains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.